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Abstract   
Background: This systematic review compares the efficacy and safety of remdesivir between its recipient and non-
recipient COVID-19 patients from the recently published randomized controlled trials (RCT).   
Methods: For eligible trials comparing the above outcomes, a literature search took place in the PubMed database. 
The reviewed trials data were abstracted and critically appraised using the Cochrane tool. Then, a random-effect meta-
analysis followed to compare the risk between the compared interventions in risk ratio (RR). By plying the I2 and Chi2 
statistics, the heterogeneity estimation happened. A sensitivity analysis iterated the preliminary meta-analysis using a 
fixed-effect model. 
Results: Two eligible RCTs included in this review sourced data from about 833 COVID-19 patients from 115 
hospitals in Asia, Europe, and the US. The risk of bias was primarily low. Random-effect meta-analysis suggested a 
clinical improvement (RR: 1.09; 95% CI: 1.02, 1.16; P=0.02; I2: 0%) and decrease in the risk of any serious side 
effects (RR: 0.64; 95% CI: 0.43, 0.94; P<0.001; I2: 0%) in the remdesivir treated COVID-19 patients. The rest of the 
outcomes did not vary between the juxtaposed interventions. 
Conclusion: Evidence-based on early RCTs suggest that remdesivir is a clinically useful and safe drug to treat 
COVID-19 patients. 
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Background  
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-
CoV-2) infection started in December 2019 in Wuhan, Hubei 
Province, China causing coronavirus disease (COVID-19) [1–
3]. As COVID-19 spread globally across the continents, the 
World Health Organization declared the COVID-19 epidemic 
as a pandemic in March 2020 [4]. As of 4th October 2020, the 
ongoing COVID-19 pandemic claimed over one million lives 
and infected almost 35 million people worldwide [5].  
     Presently, no proven vaccine or antiviral therapy exists 
against the SARS-CoV-2 virus, and several antiviral 
medications and immunomodulators are under research. In this 
regard, remdesivir, a nucleotide analog prodrug that inhibits 
viral RNA-dependent RNA polymerase (RdRp), appears 
promising in the preliminary in vivo and in vitro studies [6]. It 
has a broad spectrum of activity against viruses like a 
respiratory syncytial virus, Ebola virus, Nipah virus, Middle  
 
 
East Respiratory Syndrome, and SARS-CoV-2 [7–9]. 
Remdesivir delivers the monophosphate nucleoside analog GS-
441524 into the cells and gets converted into a 
pharmacologically active nucleoside triphosphate form GS-
443902 [10]. The latter act as an analog of adenosine 
triphosphate, and its natural substrate inhibits the RdRp 
selectively [10]. Remdesivir decreases the pulmonary infiltrates 
in SARS-CoV-2 infected rhesus macaque model [10] and 
inhibits SARS-CoV-2 replication in human nasal and bronchial 
airway epithelial cells [11]. On 03-April-2020, European 
Medical Agency approved the compassionate use of remdesivir 
in mechanically ventilated patients with severe COVID-19 [10]. 
Subsequently, on 01-May-2020, the United States Food Drug 
Administration issued Emergency Use Authorization 
permission to use the drug in COVID-19 patients [10].  
     In this period of global crisis, while the world waits for a 
definitive answer regarding the safety and efficacy of 
remdesivir in COVID-19 patients, we conducted this systematic 
review and meta-analysis to understand how the clinical 
improvement, overall and severe adverse reactions, and 
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Methods 
We followed the Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA statement (2009) 
reporting guideline to report this review. This review has no 
pre-published protocol, and it is not registered to any systematic 
review registers [12]. 
 
Inclusion criteria 
1. Study population: COVID-19 patients of any age and gender. 
2. Study design: randomized controlled trials (RCTs) of any 
duration. 3. Intervention arm:  the intervention arm should have 
received remdesivir in any dose, regimen, and route of 
administration. 4. Comparator arm: the control group may 
receive placebo or standard care or any other intervention that 
does not include remdesivir. 5. Outcome: the risk of clinical 
improvement, overall and severe adverse reactions, and 
mortality in the above-depicted patient population were the 
outcomes of interest. 
 
Debriefing at research centers  
Debriefing is an informal experience exchange session designed 
to improve team performance and effectiveness from lessons 
learned and reinforce positive behaviors. It is a high quality-
standard implemented in different industries, where the health 
industry is no exception [4]. At world-class businesses, briefing 
and debriefing are ingrained in the staff`s culture. Sharing 
debriefing minutes on public health domains helps researchers 
avoid taking unnecessary risks of trying a drug if proved 
elsewhere not to be effective. It cannot be overemphasized that 
scientists worldwide are prompted to stay connected to share 




1. We eliminated studies based on pregnant or lactating 
females. 2. Study designs other than RCTs like observational 
studies were also not included. 
 
Search strategy 
The search for eligible trials' titles and abstracts ensued in the 
PubMed database irrespective of any date, language, or 
geographical boundary. The last date of the database search was 
07-Oct-2020. Following search terms were used “coronavirus 
infections"[MeSH Terms] OR “SARS-CoV-2” OR “COVID-
19” AND “Remdesivir” NOT "middle east respiratory 
syndrome coronavirus" NOT “MERS.” To narrow the search to 
RCTs, we used the subsequent filters “Clinical Trial”, “Clinical 
Trial, Phase I”, “Clinical Trial, Phase II”, “Clinical Trial, Phase 
III”, “Clinical Trial, Phase IV”, and “Controlled Clinical Trial”. 




We uploaded the search results to a referencing software and 
skimmed through the retrieved citations' title and abstract to 
find the eligible trials. For articles that seemed to match the 
above eligibility criteria, and for those, a decision regarding the 
inclusion or exclusion from this review was not possible by 
reading the excerpts alone, a full-text reading happened. The 
review authors abstracted the study design data, population 
characteristics, compared interventions, and reported outcomes 
in a pre-piloted form. 
 
Risk of bias assessment 
The risk of bias assessment of each of the publications included 
in this review underwent judgment by the Cochrane tool [13]. 
This assessment transpired for selection, performance, 
detection, attrition, reporting, and other bias, and each of these 
went through categorization into the low, high, or unclear risk 
of bias category [13]. The random sequence generation method 
and concealment of the intervention allocation from the 
participants judged the selection bias. Utilizing the study 
participants' blinding information and the study personnel and 
that of the outcome assessors, we evaluated the performance 
and detection bias, respectively. The attrition bias assessment 
considered the missing outcome data and its balance across the 
intervention arms. By comparing the pre-specified notions of 
the trialists with their reported findings, the reporting bias 
assessment occurred. A miscellaneous bias categorization 




The review authors independently selected the studies, 
abstracted its data, critically appraised it, resolved all 
disagreements by discussion, and did not need a third-party 
opinion.     
 
Meta-analysis methodology 
We meta-analytically (random-effect; DerSimonian and Laird 
method) compared each outcome between COVID-19 infected 
remdesivir recipients and non-recipients to estimate the risk 
ratio (RR). When remdesivir testing happened in more than one 
treatment arms of a trial, we combined the outcome events 
across these for meta-analysis. We assessed the heterogeneity 
using I2 (categorized heterogeneity as low, moderate, and high 
at values 25%, 50%, and 75%, respectively) [14] and Chi2 
statistics (statistically significant at P<0.1). A publication bias 
assessment did not happen as <10 trials were available for 
meta-analysis. Sensitivity analysis iterated the preliminary 
meta-analysis using a fixed-effect model. All analyses occurred 
in the Stata statistical software (version 16), and P<0.05 was the 
demarcation used for statistical significance estimation. 
    
Results  
Scope of this review 
The database search retrieved six citations. There were no 
duplicates. Four articles not matching the eligibility criteria 
were excluded. The adjunct search in the bibliography of the 
reviewed trials did not reveal any additional articles. Figure 1 
demonstrates the study selection process. In this systematic 
review, we included two RCTs matching the above inclusion 
criteria. These trials sourced data from about 833 COVID-19 
patients from 115 hospitals in Asia, Europe, and the US [15,16]. 
In both the trials, the patients received the intravenous 
remdesivir of 200 mg on the first day and 100 mg on the 
successive nine days [15,16]. In one trial, some participants 
received the regimen for five days (instead of 10 days) [16]. 
The comparator arm received a placebo and standard care in the 
respective trials [15,16]. Table 1 presents the salient features of 
these trials. 







































                     
         Figure 1 PRISMA 2009 diagram 
 
 
Risk of bias assessment 
Overall, the trials had a low risk of bias, except for detection 
and performance bias, for which the risk of bias was unclear. 




Meta-analytic findings using the random-effect model 
suggested a clinical improvement (RR: 1.09; 95% CI: 1.02, 
1.16; P =0.02; I2: 0%; P of Chi2: 0.72) and decrease in the risk 
of any serious side effects (RR: 0.64; 95% CI: 0.43, 0.94; P 
<0.001; I2: 0%; P of Chi2: 0.75) in remdesivir treated COVID-
19 patients. Any adverse event (RR: 1.05; 95% CI: 0.85, 1.31) 
and mortality (RR: 0.97; 95% CI: 0.52, 1.79) risk did not vary 
between the compared interventions (Figure 2). Sensitivity  
analysis iterating the meta-analyses using a fixed-effect model 
replicated the above findings. 
 
Discussion 
Overall, we found two RCTs testing remdesivir in over 800 








































North America. Remdesivir treated patients had better clinical 
outcomes and less risk of serious adverse events.   
 
Contrast with existing literature 
One meta-analysis article found that remdesivir treatment in 
COVID-19 patients reduced the risk of serious side effects [17]. 
Regarding mortality, it demonstrated that mortality decrease in 
these patients was seen on day 14 of treatment and not on day 
28 of treatment [17]. Another review article reported that 
remdesivir treatment in COVID-19 patients did not reduce the 
all-cause mortality after five and14 days of follow-up [18]. 
Although we did not look into mortality at different timepoints 
and accounted for the cumulative deaths that happened in each 
of the trials over its entire follow-up, we found that on 
remdesivir use, mortality did not decline, and the risk of serious 
side effects decreased. Our study was different in terms that we 
did not account for the events that happened after every time 
period after which different outcomes were reported and looked 
into the cumulative outcome at the end of the trial period.       
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Figure 2. Forest plots comparing the effect of Remdesivir with no 
Remdesivir. Outcomes: 2a. Clinical improvement 2b. Any adverse 
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Table 1 Salient features of reviewed papers  
Study Participants Interventions Interventions Outcomes 
Spinner, 
2020[16] 











Diagnosis: SARS-CoV-2 infected 
hospitalized patients  
Randomized (n) = 596 patients from 
105 hospitals 
Minimum age of eligibility: 12 years 
Age (median, IQR): 10-day 
Remdesivir: 56 (45-66) years; 5-day 
Remdesivir: 58 (48-66) years; 
Standard care: 57 (45-66) years 
Consent: obtained. 
Country: US, Europe, Asia 
Three intervention arms: 
1. 10-day course of Remdesivir 
2. 5-day course of Remdesivir  
3. Standard care 
 
Remdesivir groups received it 
intravenously at a dosage of 
200 mg on day one followed 
by 100mg daily on day 2-10. 
1. Clinical improvement 
2. Any adverse event 















Diagnosis: SARS-CoV-2 infected 
patients with pneumonia  
Randomized (n) = 237 patients from 
10 hospitals 
Minimum age of eligibility: 18 years 
Age (median, IQR): Remdesivir 




Two intervention arms: 
1. Remdesivir treatment arm 
2. Placebo arm 
 
Remdesivir groups received it 
intravenously at a dosage of 
200 mg on day one followed 
by 100mg daily on day 2-10. 
1. Clinical improvement 
2. Any adverse event 
3. Any serious side effects  
4. Mortality 
Abbreviation: IQR, interquartile range; SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2 
 
 





























Low Unclear Unclear Unclear Low Low Low 
  Reviewers’ comment: open label trial    
Wang, 
2020[15] 
Low Low Unclear Unclear Low Low Low 
 
 
Strengths and weaknesses 
Our review has several strong points. At present, when the 
COVID-19 pandemic is still emerging and claiming human life 
at an extraordinarily high pace, this is perhaps the only human-
clinical-trial-based cumulative evidence available in the context 
of efficacy and safety of remdesivir. Moreover, this review's 
search strategy was perhaps comprehensive enough to identify 
all eligible trials as we did not restrict it to any date, language, 
or geographic boundary. Besides, RCTs' inclusion only, 
plausibly ensured rigor to the evidence we generated as these 
type of studies is considered the highest level of 
epidemiological evidence. Additionally, despite fewer trials, as 
the sample size was relatively large and originated from a 
geographically diverse territory, we expect our findings to be 
externally valid. However, there are a few weaknesses in our 
review. This review does not have a pre-published/registered 
protocol. Next, we could not account for the remdesivir-related 
evidence that sources from observational studies since our 
eligibility criteria did not allow us to review these studies. Then, 
as stated above, the publication bias evaluation was not possible 
due to fewer available trials. Lastly, at the trial level, there was 




This evidence review suggests that remdesivir is a relatively 
safe drug to use in COVID-19 infected hospitalized patients.  
Those treated with remdesivir experienced clinical 
improvement and a decreased risk of severe side effects. The 
geographic diverseness of the study population plausibly 
ensures the generalizability of these findings. 
 
Abbreviation  
RCT: Randomized Controlled Trials; PR: Risk Ratio; SARS-CoV-2: 
Severe Acute Respiratory Syndrome-Coronavirus-2; COVID-19: 
Coronavirus Disease; RdRp: RNA-dependent RNA polymerase; 
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-
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